And more drug company shenanigans

New york times today shows that drug company shenanigans know no bounds (ie, not just in US!!).  Johnson and Johnson seems to have paid off Novartis to keep them from releasing a generic version of fentanyl in the Netherlands.  See link below.  Geoff
 
 

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

Very low LDL levels: benefit without harm

​ A recent meta-analysis of lipid-lowering shows that remarkably low levels of LDL cholesterol provide clinical cardiovascular benefit with no clear  increased harm  (see  lipids very low LDL benefit JAMAcardiol2018  in dropbox, or doi:10.1001/jamacardio.2018.2258). Details: -- 4 trials were looked at:     -- the Cholesterol Treatment Trialists Collaboration (CTTC), a meta-analysis of several RCTs that compared different LDLs achieved through statins, median follow-up of 4.9 years, 1922 vascular events     -- 3 RCTs evaluated non-statin LDL lowering therapies:         -- IMPROVE-IT study with ezetimibe (n= 18,144), median follow-up 6.0 years, 5104 vascular events         -- FOURIER study with the PCSK9 inhibitor evolocumab (n=2,034), median follow-up 2.1 years, 184 vascular events         -- RE...
Read more

PCSK9 inhibitors (vs statins) and diabetes

  There is concern about an increased risk of diabetes in patients taking statins. A recent study of patients taking PCSK9 inhibitors, however, found that there was not a clear relationship for them with developing diabetes (see   lipid PCSK9 and diabetes CurrentAtheroRep2022 , or doi.org/10.1007/s11883-022-01074-y).   Details:  -- this study involved an evaluation of the cardiovascular outcomes of the FOURIER (using evolocumab) and ODYSSEY (using alirocumab) trials,  meta-analyses,  Mendelian randomization trials, and post-marketing safety reports -- Main outcome: new-onset diabetes (NOD) rates in patients on PCSK9 inhibitors   Results:  -- FOURIER trial with evolocumab:      -- 25,982 patients on evolocumab found a monotonic relationship between achieved LDL and major cardiovascular outcomes, down to an LDL <20mg/dL ( cad high risk LDL less than 20 fourier studyCirc2023  in dropbox, or DOI: 10.1161/CIRCULATI...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more